These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34565254)

  • 1. Case report: Proton pump inhibitor drug-related problem in pancreatic cancer patient unmasks pancreatic enzyme insufficiency.
    Giani J; Chambers CR; Sawyer MB
    J Oncol Pharm Pract; 2022 Mar; 28(2):457-461. PubMed ID: 34565254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omeprazole-induced and pantoprazole-induced asymptomatic hyponatremia: a case report.
    van der Zalm IJB; Tobé TJM; Logtenberg SJJ
    J Med Case Rep; 2020 Jun; 14(1):83. PubMed ID: 32594911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palliative Chemotherapy: Does It Only Provide False Hope? The Role of Palliative Care in a Young Patient With Newly Diagnosed Metastatic Adenocarcinoma.
    Doverspike L; Kurtz S; Selvaggi K
    J Adv Pract Oncol; 2017; 8(4):382-386. PubMed ID: 30018843
    [No Abstract]   [Full Text] [Related]  

  • 5. Delayed Presentation of DPD Deficiency in Colorectal Cancer.
    Law L; Rogers J; Eng C
    J Adv Pract Oncol; 2014 May; 5(3):205-10. PubMed ID: 25089219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole.
    Gouraud A; Vochelle V; Descotes J; Vial T
    Clin Drug Investig; 2010; 30(8):559-63. PubMed ID: 20586518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
    Devault KR
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):197-205. PubMed ID: 19072410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication.
    Semb S; Helgstrand F; Hjørne F; Bytzer P
    World J Gastroenterol; 2017 Oct; 23(37):6907-6910. PubMed ID: 29085234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton Pump Inhibitor Induced Hypomagnesemia Causing Seizures: A Rare Adverse Effect of a Commonly Used Medication.
    Krishnan M; Fernando H; Mohammed HH; Vithanage N
    Cureus; 2024 Jul; 16(7):e64044. PubMed ID: 39114244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with pantoprazole in gastroesophageal reflux disease.
    Avner DL
    Clin Ther; 2000 Oct; 22(10):1169-85; discussion 1149-50. PubMed ID: 11110229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test.
    Armstrong D; Veldhuyzen SJ; Chung SA; Shapiro CM; Dhillon S; Escobedo S; Chakraborty BK; Mann V; Tanser L; Nevin K
    Can J Gastroenterol; 2005 Jun; 19(6):350-8. PubMed ID: 15997268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
    Metz DC
    Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.
    Poe RH; Kallay MC
    Chest; 2003 Mar; 123(3):679-84. PubMed ID: 12628862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.
    Pilotto A; Franceschi M; Rassu M; Leandro G; Bozzola L; Furlan F; Di Mario F
    Dig Liver Dis; 2000 Nov; 32(8):667-72. PubMed ID: 11142574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pantoprazole: a proton pump inhibitor.
    Moreira Dias L
    Clin Drug Investig; 2009; 29 Suppl 2():3-12. PubMed ID: 19938880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Utilization Study of Gastroprotective Agents in Medicine and Surgery Wards of a Tertiary Care Teaching Hospital.
    Koyani H; Vora N; Kalathia M; Patel N; Shah S
    Cureus; 2023 Jan; 15(1):e33739. PubMed ID: 36793848
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.